pazopanib + trametinib

Combination of the multikinase VEGF pathway inhibitor pazopanib and the MEK1/2 inhibitor trametinib, investigated as an oral targeted therapy regimen to achieve vertical inhibition of the VEGF–RAS–RAF–MEK–ERK pathway in solid tumors. Pazopanib inhibits VEGFR1-3, PDGFR, KIT and related kinases to suppress angiogenesis, while trametinib inhibits MEK1/2 to block MAPK signaling downstream of receptor tyrosine kinases. Clinical studies reported tolerability at or near single-agent doses but generally modest activity in soft tissue sarcoma and cholangiocarcinoma, with some clinical activity observed in differentiated thyroid cancer expansion cohorts; additive or cumulative toxicity has been described. Typical dosing explored: pazopanib 800 mg once daily with trametinib 2 mg once daily, continuous 28‑day cycles.

Brand names

Votrient + Mekinist

Other names

pazopanib plus trametinibtrametinib plus pazopanib